Regulatory Professionals employees Sarah Goddard, Divisional Director and Kirsty Calow, Divisional Manager will be exhibiting at the 2018 TOPRA Symposium, which is taking place in Sweden October 1-3rd. The Symposium features the following: Information on the latest regulatory developments Insight provided directly from Regulatory experts Opportunity for delegates to expand on their existing knowledge of
Director of Regulatory AffairsRegulatory ProfessionalsCambridgeshire, UK
- FULL TIME
Senior Regulatory Affairs AssociateRegulatory ProfessionalsBuckinghamshire, UK
- FULL TIME
Senior Regulatory Affairs ManagerRegulatory ProfessionalsWiltshire, UK
- FULL TIME
Senior Regulatory SpecialistRegulatory ProfessionalsLondon East, UK
- FULL TIME
Regulatory Professionals is one of the fastest growing global integrated regulatory outsourcing providers with a network of 20,000 pharmaceutical professionals globally. Working exclusively within the regulatory functions of Pharmaceutical, Biotechnology, Medical Device, Consumer health / OTC and Diagnostics industries.
Our integrated regulatory affairs recruitment team is there to support partner organisations of all sizes. Ranging for one regulatory consultant, to deliver a specialist project, to outsourcing functional regulatory teams of over 100+, Regulatory Professionals are able to offer global support partnered with expert local knowledge. Our capabilities also offer contract and permanent regulatory staffing services to allow a 360 degree service range for all aspects of regulatory delivery.
Our regulatory recruitment teams approach is tailored to meet the needs of our partners requirements allowing you to shift internal R&D focus to more strategic activities to improve lifecycle performance.
The benefits of Regulatory Professionals integrated teams are measured not just in the savings that could result in multi-mullion dollar cost reductions, but equally in understanding that delays in any part of the regulatory cycle affect the ability to give patients access to transformational products.
Our integrated teams support your product portfolio by giving you flexibility of resource at the peaks and troughs of the product life cycle, while ensuring you maintain control of strategic regulatory departments. This is supported by consistent, measurable and tracked metrics to maximise accountability.
To find out more about each of the regulatory areas we specialise in, take a look at the following regulatory recruitment services:
Our experienced specialist recruitment consultants are available to speak to you confidentially about our outsourcing regulatory affairs services. To find out more information or to discuss any of our regulatory vacancies, please call our specialist regulatory affairs recruitment team.
Contact us today to find out how we can progress your career to the next level
FDA are conducting a priority review of MSD’s Keytruda, a treatment for adult and paediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). This application is based on data from the Phase II KEYNOTE-017 trial, which showed an objective response rate of 56% at 14.9 months in patients taking the immunotherapy, including
Mepsevii has been approved for use in Europe to treat the ultra-rare disease mucopolysaccharidosis type VII (MPS VII), offering patients an approved treatment for the very first time. MPS VII, also known as Sly Syndrome, is a genetic metabolic lysosomal storage disorder, caused by the deficiency of beta-glucuronidase, an enzyme required for the breakdown of